Paul Blake
Directeur Général chez Papyrus Therapeutics, Inc.
Profil
Paul Blake is the founder of Papyrus Therapeutics, Inc. He currently holds positions as a Member of The Royal College of Physicians, a Member of the Faculty of Pharmaceutical Medicine, and a Member of the American College of Clinical Pharmacology.
In the past, he held positions such as Director at ViaCell, Inc., Memory Pharmaceuticals Corp., and MDS Proteomics, Inc. He was also the Chief Medical Officer at Heron Therapeutics, Inc., Synageva BioPharma Corp., and InfaCare Pharmaceutical Corp.
Additionally, he was the EVP-Worldwide Medical & Regulatory Operations at Cephalon, Inc. and the Chief Development Officer at Oxford Biomedica Plc.
He has also served as a Trustee for The Children's Health Fund.
Dr. Blake earned a doctorate degree from the University of London.
Postes actifs de Paul Blake
| Sociétés | Poste | Début |
|---|---|---|
| The Royal College of Physicians | Corporate Officer/Principal | - |
| Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | - |
American College of Clinical Pharmacology
 American College of Clinical Pharmacology Miscellaneous Commercial ServicesCommercial Services The American College of Clinical Pharmacology (ACCP) is an organization that focuses on clinical pharmacology. The American company's personal data privacy policy and procedure outlines how they collect, use, share, and protect personal data from their users. | Corporate Officer/Principal | - |
Papyrus Therapeutics, Inc.
 Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Directeur Général | - |
Anciens postes connus de Paul Blake
| Sociétés | Poste | Fin |
|---|---|---|
| CV SCIENCES, INC. | Directeur/Membre du Conseil | 26/05/2022 |
| OXFORD BIOMEDICA PLC | Corporate Officer/Principal | 31/08/2016 |
| AETERNA ZENTARIS INC. | Directeur Technique/Scientifique/R&D | - |
Memory Pharmaceuticals Corp.
 Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | Directeur/Membre du Conseil | 06/01/2009 |
Protez Pharmaceuticals, Inc.
 Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Directeur/Membre du Conseil | - |
Formation de Paul Blake
| University of London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AETERNA ZENTARIS INC. | Health Technology |
| OXFORD BIOMEDICA PLC | Health Technology |
| ANNOVIS BIO, INC. | Health Technology |
| HERON THERAPEUTICS, INC. | Health Technology |
| CV SCIENCES, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Protez Pharmaceuticals, Inc.
Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | Health Technology |
| MDS Proteomics, Inc. | Commercial Services |
Synageva BioPharma Corp. /Old/
 Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
| Smithkline Beecham Pharmaceuticals Ltd. | |
The Children's Health Fund
 The Children's Health Fund Medical/Nursing ServicesHealth Services The Children's Health Fund is a non-profit organization, which engages in the provision of healthcare services for kids. It offers Blue Bus, a pediatric mobile medical clinic that offers curbside checkups and treatments. The firm also supports the Terra Firma project, a program the provides healthcare, mental health support, and legal assistance for unaccompanied immigrant minors. The company was founded by Irwin E. Redlener, Karen B. Redlener, and Paul Simon in 1987 and is headquartered in New York, NY. | Health Services |
AstraZeneca, Inc.
 AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Health Technology |
G.D. Searle & Co., Inc.
 G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
Y-Prime LLC
 Y-Prime LLC Packaged SoftwareTechnology Services Y-Prime LLC provides eClinical software and professional services. It offers patient and IP management, site monitoring, clinical outcomes, supply forecasting and professional services. The company was founded by Shawn Blackburn and Jaime Cook in 2006 and is headquartered in Malvern, PA. | Technology Services |
InfaCare Pharmaceutical Corp.
 InfaCare Pharmaceutical Corp. BiotechnologyHealth Technology InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA. | Health Technology |
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
| Faculty of Pharmaceutical Medicine | |
American College of Clinical Pharmacology
American College of Clinical Pharmacology Miscellaneous Commercial ServicesCommercial Services The American College of Clinical Pharmacology (ACCP) is an organization that focuses on clinical pharmacology. The American company's personal data privacy policy and procedure outlines how they collect, use, share, and protect personal data from their users. | Commercial Services |
Papyrus Therapeutics, Inc.
Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Commercial Services |
